Category Archives: Mesenchymal Stem Cells

PALO ALTO, Calif., July 11, 2013 /PRNewswire/ --Cellular Biomedicine Group, Inc. (CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced the appointment of Maxwell Wang, M.D., PhD, as Director of Medical Research. Dr. Wang received his MD degree from Wuerzburg University in Germany and PhD degree from University of Aberdeen, UK, following which he continued extensive research at the University of Connecticut Health Center. During his academia Dr. Wang was the first to find the paracrine and autocrine effects of CCN family genes (genes relating to connective tissue growth) in bone cell differentiation and the capability of bone marrow-derived CTGF-GFP cells to increase bone formation. Dr. Wang is an orthopedic surgeon with over 10 years of experience in academic research focused on mesenchymal stem cells and bone cells. Dr. Chase Dai, VP and GM of CBMG's Autologous Products Business Unit, commented, "Dr. Wang's extensive experience in the field of stem cells, particularly as applied to orthopedics, will be a valuable asset to our Knee Osteoarthritis program which is currently in clinical trial." About Cellular Biomedicine GroupCellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and … Continue reading →

What makes Guided Mesenchymal Stem Cell Layering for osteoarthritis treatment different? http://www.stemcellsarthritistreatment.com With all the various methods of stem cell treatment for osteoarthritis, how does one know which one to choose? You... By: Nathan Wei … Continue reading →

Albany, New York (PRWEB) July 12, 2013 According to a new market report published by Transparency Market Research "Stem Cells Market (Adult, Human Embryonic , Induced Pluripotent, Rat-Neural, Umbilical Cord, Cell Production, Cell Acquisition, Expansion, Sub-Culture)- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," the market for stem cells was valued at USD 26.23 billion in 2011 and is expected to reach an estimated value of USD 119.51 billion in 2018, growing at a CAGR of 24.2% from 2012 to 2018. Related Report : Coronary Stents Market http://www.transparencymarketresearch.com/coronary-stents-market.html Stem cells are undifferentiated cells which are capable of differentiating into any type of cell that make-up the human body and thus, are capable of producing non-regenerative cells such as neural and myocardial cells. This report estimates the market for global stem cells in terms of revenue (USD billion) for the period 2012 2018, keeping 2011 as the base year. The global stem cells market is mainly segmented into four major sub-types namely market by products, market by technology, market by applications and market by geography. The market by products is segmented into three sub-types, namely adult stem cells, human embryonic stem cells and other type of stem … Continue reading →

Public release date: 12-Jul-2013 [ | E-mail | Share ] Contact: Bruce Goldman 650-725-2106 Stanford University Medical Center STANFORD, Calif. A new, noninvasive technique for tracking stem cells after transplantation developed by a cross-disciplinary team of radiologists, chemists, statisticians and materials scientists at the Stanford University School of Medicine could help surgeons determine whether a procedure to repair injured or worn-out knees is successful. The technique, described in a study to be published online July 12 in Radiology, relies on an imaging agent already approved by the U.S. Food and Drug Administration for an entirely different purpose: anemia treatment. Although this study used rodents, the approach is likely to be adapted for use in humans this fall as part of a clinical trial in which mesenchymal stem cells will be delivered to the site of patients' knee injuries. Mesenchymal stem cells are capable of differentiating into bone and cartilage, as well as muscle, fat and tendon, but not into the other cell types that populate the body. Every year, arthritis accounts for 44 million outpatient visits and 700,000 knee-replacement procedures. But the early repair of cartilage defects in young patients may prevent further deterioration of the joint and the need … Continue reading →

SAN DIEGO, July 10, 2013 /PRNewswire/ --ViaCyte, Inc., a leading regenerative medicine company focused on developing new approaches to treat major diseases through the application of a stem cell-derived cell therapy, announced today that it completed a private equity financing transaction, providing the Company $10.6 million through the sale of Series C-1 Preferred Stock, together with warrants to purchase stock. The financing, conducted as a rights offering to ViaCyte Series B and C Preferred Stock holders, included the Company's largest existing investors - Johnson & Johnson Development Corporation, Sanderling Ventures and Asset Management Company (Johnson Trust). (Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a) This funding serves as a match for a $10.1 million Strategic Partnership Award (SPA) that was approved last October by the California Institute for Regenerative Medicine (CIRM) to support clinical evaluation of VC-01, ViaCyte's promising encapsulated cell-therapy product being developed as a transformative therapy for patients with type 1 and insulin-dependent type 2 diabetes. In addition, ViaCyte may sell additional shares of Series C-1 Preferred Stock and warrants in one or more subsequent closings that may occur during the remainder of 2013. The Company will use the funds to pursue clinical development of VC-01. VC-01 is a development-stage product that consists of … Continue reading →

EATONTOWN, N.J., July 10, 2013 (GLOBE NEWSWIRE) -- American CryoStem Corporation (CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that its protocols for the processing of Stromal Vascular Fraction (SVF) and culturing of mesenchymal stem cells from autologous adipose tissue have been approved by the Institutional Review Board (IRB) of the International Cell Surgical Society (ICSS). The two protocols are titled: 1) Autologous Adipose Tissue-Derived Stromal Vascular Fraction (SVF) Containing Adult Stem Cells with Isolation of SVF and 2) Culturing of Adipose Derived Stem Cells (ADSCs) For Use in Institutional Review Board Studies. These protocols provide appropriate testing methods necessary to move the clinical investigative process towards uniform treatments, and the collection of cGMP processing and outcome data required by prevailing FDA regulations and guidance for approval of regenerative cellular therapies, including potency (cell count), contamination testing and cell viability. The Company will make available its processing services utilizing the IRB approved protocols to physicians and clinical researchers for inclusion in their studies. By adopting these protocols and the laboratory services of American CryoStem, researchers can focus their resources on application development rather than … Continue reading →

06) M. Rojas Mesenchymal stem cells loose regulatory functions in patients with idiopathic pulmonary fibrosis Iclaf 2012 October 3, 2012 Modena, Complesso San Geminiano 1... By: tvunimore … Continue reading →

Findings show that miR-22 plays a key role in both breast cancer and blood cancer Newswise BOSTON A mere 25 years ago, noncoding RNAs were considered nothing more than background noise in the overall genomic landscape. Now, two new studies reveal that one of these tiny noncoding molecules microRNA-22 plays an outsized role in two types of cancer. Reported on-line July 3 in the journals Cell and Cell Stem Cell, the two papers demonstrate in mouse models that miR-22 drives both the onset and spread of breast cancer, as well as the onset of blood cancer. The findings, led by investigators at Beth Israel Deaconess Medical Center (BIDMC), further suggest that inhibition of miR-22 through a decoy method offers a novel therapeutic option for treating hematological malignancies. This is the first time that a microRNA has been shown to drive both cancer initiation and metastasis in a mouse model, explains senior author Pier Paolo Pandolfi, MD, PhD, Scientific Director of the Cancer Center at BIDMC and the George Reisman Professor of Medicine at Harvard Medical School. Its amazing that, by itself, this one little microRNA can trigger cancer in two different organs, perhaps in many more, and in the case … Continue reading →

Public release date: 3-Jul-2013 [ | E-mail | Share ] Contact: Bonnie Prescott bprescot@bidmc.harvard.edu 617-667-7306 Beth Israel Deaconess Medical Center BOSTON -- A mere 25 years ago, noncoding RNAs were considered nothing more than "background noise" in the overall genomic landscape. Now, two new studies reveal that one of these tiny noncoding molecules microRNA-22 plays an outsized role in two types of cancer. Reported on-line today in the journals Cell and Cell Stem Cell, the two papers demonstrate in mouse models that miR-22 drives both the onset and spread of breast cancer, as well as the onset of blood cancer. The findings, led by investigators at Beth Israel Deaconess Medical Center (BIDMC), further suggest that inhibition of miR-22 through a "decoy" method offers a novel therapeutic option for treating hematological malignancies. "This is the first time that a microRNA has been shown to drive both cancer initiation and metastasis in a mouse model," explains senior author Pier Paolo Pandolfi, MD, PhD, Scientific Director of the Cancer Center at BIDMC and the George Reisman Professor of Medicine at Harvard Medical School. "It's amazing that, by itself, this one little microRNA can trigger cancer in two different organs, perhaps in many more, … Continue reading →

Source: ONE News A functioning human liver has been successfully grown in a mouse by scientists in Japan, opening up the prospect of a future where replacement organs are grown on demand. The ground-breaking research, published in the latest edition of Nature, involved the scientists creating a liver "bud" in a laboratory using stem cells and then transplanting it into the rodent. The tiny but functioning human liver matured after being transplanted into the mouse, developing a vascular system and performing liver-specific functions. Takanori Takebe and Hideki Taniguchi, of the Yokohama City University Graduate School of Medicine, said the breakthrough proved the concept of organ bud transplantation for the first time. "Although efforts must ensue to translate these techniques to treatments for patients, this proof-of-concept demonstration of organ-bud transplantation provides a promising new approach to study regenerative medicine," the researchers said. Tests on the mouse showed the minute liver, which measured just half a centimetre, was able to perform liver-specific functions such as protein production and human-specific drug metabolism. "These results highlight the enormous therapeutic potential using in vitro-grown organ-bud transplantation for treating organ failure," the study concluded. While it may take another 10 years before lab-grown livers could be … Continue reading →